Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
15
08
2022
accepted:
14
12
2022
revised:
11
12
2022
pubmed:
18
1
2023
medline:
3
3
2023
entrez:
17
1
2023
Statut:
ppublish
Résumé
Exploring the relationship between various neurotransmitters and breast cancer cell growth has revealed their likely centrality to improving breast cancer treatment. Neurotransmitters play a key role in breast cancer biology through their effects on the cell cycle, epithelial mesenchymal transition, angiogenesis, inflammation, the tumor microenvironment and other pathways. Neurotransmitters and their receptors are vital to the initiation, progression and drug resistance of cancer and progress in our biological understanding may point the way to lower-cost and lower-risk antitumor therapeutic strategies. This review discusses multiple neurotransmitters in the context of breast cancer. It also discusses risk factors, repurposing of pharmaceuticals impacting neurotransmitter pathways, and the opportunity for better integrated models that encompass exercise, the intestinal microbiome, and other non-pharmacologic considerations. Neurotransmitters' role in breast cancer should no longer be ignored; it may appear to complicate the molecular picture but the ubiquity of neurotransmitters and their wide-ranging impacts provide an organizing framework upon which further understanding and progress against breast cancer can be based.
Identifiants
pubmed: 36650218
doi: 10.1038/s41388-022-02584-4
pii: 10.1038/s41388-022-02584-4
pmc: PMC9957733
doi:
Substances chimiques
Neurotransmitter Agents
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
627-637Subventions
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Eur Rev Med Pharmacol Sci. 2016 Aug;20(16):3500-6
pubmed: 27608913
J Pers Med. 2020 Oct 29;10(4):
pubmed: 33138097
Breast Cancer Res Treat. 2021 Jul;188(2):427-432
pubmed: 33837871
Sci Rep. 2016 Jan 27;6:19771
pubmed: 26813959
Oncotarget. 2017 Jan 24;8(4):6446-6460
pubmed: 28031536
J Histochem Cytochem. 2022 Apr;70(4):311-322
pubmed: 35227109
ESMO Open. 2021 Apr;6(2):100066
pubmed: 33639601
Cancer Prev Res (Phila). 2013 Dec;6(12):1262-72
pubmed: 24309563
Peptides. 2013 Oct;48:106-13
pubmed: 23932937
Ann Oncol. 2017 Aug 01;28(8):1836-1841
pubmed: 28520849
Nat Rev Cancer. 2020 Mar;20(3):143-157
pubmed: 31974491
Surg Oncol. 2019 Dec;31:46-53
pubmed: 31536927
Breast Cancer Res Treat. 2013 Aug;140(3):567-75
pubmed: 23912960
Biochem Biophys Res Commun. 2006 May 19;343(4):1053-9
pubmed: 16580628
Oncogene. 2020 Jan;39(3):503-515
pubmed: 31527667
Br J Cancer. 2020 Feb;122(3):348-360
pubmed: 31748740
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32436935
Front Oncol. 2020 Jul 14;10:1130
pubmed: 32760671
Rev Esc Enferm USP. 2019 Dec 02;53:e03529
pubmed: 31800820
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):984-9
pubmed: 24395782
Curr Clin Pharmacol. 2019;14(2):91-100
pubmed: 30501602
Br J Cancer. 2002 Jan 7;86(1):92-7
pubmed: 11857018
Psychoneuroendocrinology. 2021 Apr;126:105163
pubmed: 33611132
Biochem Pharmacol. 2020 Oct;180:114177
pubmed: 32721509
Semin Immunopathol. 2020 Dec;42(6):719-734
pubmed: 32948909
Indian J Cancer. 2020 Jul-Sep;57(3):234-238
pubmed: 32769293
Molecules. 2021 May 26;26(11):
pubmed: 34073226
Cancers (Basel). 2021 Jan 21;13(3):
pubmed: 33494360
Sci Rep. 2017 Apr 04;7:45686
pubmed: 28374823
Psychoneuroendocrinology. 2019 Jan;99:191-195
pubmed: 30253326
PLoS One. 2021 Dec 1;16(12):e0260481
pubmed: 34852013
Oncotarget. 2019 Mar 12;10(21):2055-2067
pubmed: 31007848
Cancer Med. 2019 Dec;8(18):7603-7612
pubmed: 31663690
Biochem Biophys Res Commun. 2022 Dec 17;634:100-107
pubmed: 36242915
Breast Cancer Res Treat. 2011 Jan;125(2):351-62
pubmed: 20237834
Nat Commun. 2020 Jul 17;11(1):3606
pubmed: 32681016
Breast Cancer Res Treat. 2017 Oct;165(3):585-592
pubmed: 28674764
Pharmaceuticals (Basel). 2020 May 26;13(6):
pubmed: 32466499
J Clin Oncol. 2011 Jul 1;29(19):2635-44
pubmed: 21632503
Cancers (Basel). 2021 Jun 09;13(12):
pubmed: 34207620
Clin Breast Cancer. 2015 Dec;15(6):426-31
pubmed: 26516037
Eur Rev Med Pharmacol Sci. 2016;20(1):157-65
pubmed: 26813469
Oncogene. 2016 Jan 7;35(1):47-58
pubmed: 25798840
Nat Commun. 2016 Feb 12;7:10715
pubmed: 26869349
Epidemiology. 2003 May;14(3):307-14
pubmed: 12859031
Front Oncol. 2022 Feb 09;12:795864
pubmed: 35223475
Future Oncol. 2021 Mar;17(9):1105-1124
pubmed: 33543643
Brain Behav Immun. 2016 Mar;53:223-233
pubmed: 26718447
Oncotarget. 2017 May 9;8(19):32101-32116
pubmed: 28404880
Cancers (Basel). 2021 Sep 28;13(19):
pubmed: 34638341
Front Oncol. 2022 Jan 26;12:811716
pubmed: 35155248
Br J Anaesth. 2019 Dec;123(6):865-876
pubmed: 31591020
Eur J Cancer Prev. 2016 Sep;25(5):440-8
pubmed: 26340056
Oncology. 2017;92(5):264-268
pubmed: 28132057
Medicine (Baltimore). 2014 Dec;93(27):e172
pubmed: 25501061
Int J Epidemiol. 2022 Jun 13;51(3):807-816
pubmed: 35134960
Med J Islam Repub Iran. 2020 Aug 17;34:99
pubmed: 33315977
Gynecol Endocrinol. 2022 May;38(5):385-390
pubmed: 35266411
Am J Epidemiol. 2000 May 15;151(10):951-7
pubmed: 10853633
Breast Cancer Res Treat. 2022 May;193(1):225-235
pubmed: 35286523
Cell Death Differ. 2021 Sep;28(9):2778-2796
pubmed: 33963313
Metabolomics. 2022 Jan 6;18(1):9
pubmed: 34989902
Trends Cancer. 2022 Feb;8(2):110-122
pubmed: 34776398
Cancer Res. 2001 Jun 1;61(11):4636-41
pubmed: 11389101
BMC Cancer. 2014 Aug 16;14:598
pubmed: 25129445
Crit Rev Oncol Hematol. 2019 Jun;138:173-177
pubmed: 31092374
Sci Rep. 2022 Jan 31;12(1):1648
pubmed: 35102266
Sci Rep. 2020 Sep 9;10(1):14824
pubmed: 32908180
Cancer Res. 2006 Jun 15;66(12):6243-9
pubmed: 16778199
Oncotarget. 2010 Nov;1(7):628-38
pubmed: 21317458
ACS Med Chem Lett. 2017 Sep 14;8(10):1072-1076
pubmed: 29057053
Anticancer Res. 2013 Feb;33(2):363-70
pubmed: 23393325
Front Endocrinol (Lausanne). 2021 Aug 06;12:705499
pubmed: 34421823
Cancer Treat Rev. 2018 Nov;70:178-189
pubmed: 30227299
Breast Cancer Res Treat. 2012 Dec;136(3):635-45
pubmed: 23139055
Front Cell Neurosci. 2017 Nov 03;11:336
pubmed: 29163048
Biomed J. 2019 Jun;42(3):155-165
pubmed: 31466709
Ann Transl Med. 2020 Apr;8(8):531
pubmed: 32411754
Transl Cancer Res. 2021 Nov;10(11):4817-4828
pubmed: 35116334
Sci Rep. 2021 Jan 13;11(1):1250
pubmed: 33441923
Cancers (Basel). 2021 May 28;13(11):
pubmed: 34071395
Br J Pharmacol. 2013 Sep;170(1):188-99
pubmed: 23425150
Oncoscience. 2017 Aug 23;4(7-8):95-105
pubmed: 28966942
J Clin Invest. 2014 Jul;124(7):2891-908
pubmed: 24865426
Onco Targets Ther. 2018 Aug 20;11:4913-4944
pubmed: 30174436
Oncotarget. 2016 Aug 16;7(33):53137-53152
pubmed: 27447971
Transl Oncol. 2022 Jan;15(1):101281
pubmed: 34875482
Cancer Commun (Lond). 2021 Nov;41(11):1183-1194
pubmed: 34399040
Curr Med Chem. 2022;29(18):3231-3260
pubmed: 34711154
Nature. 2011 Aug 21;477(7364):349-53
pubmed: 21857681
Sci Transl Med. 2020 Dec 2;12(572):
pubmed: 33268511
Int J Epidemiol. 2003 Dec;32(6):961-6
pubmed: 14681256
Breast Cancer Res. 2022 May 14;24(1):33
pubmed: 35568869
Mol Biol Evol. 2022 Apr 11;39(4):
pubmed: 35277960
NPJ Breast Cancer. 2022 Nov 4;8(1):116
pubmed: 36333352
J Cell Physiol. 2020 Apr;235(4):3142-3156
pubmed: 31566722
Cancers (Basel). 2022 Apr 08;14(8):
pubmed: 35454788
Nat Commun. 2021 Jun 10;12(1):3530
pubmed: 34112755
J Clin Oncol. 2011 Jul 1;29(19):2645-52
pubmed: 21632501
Neoplasma. 2019 Nov;66(6):963-970
pubmed: 31607128
Clin Cancer Res. 2020 Apr 15;26(8):1803-1811
pubmed: 31754048
Semin Cell Dev Biol. 2021 Jun;114:159-170
pubmed: 33109441
Br J Cancer. 2020 Jan;122(2):194-208
pubmed: 31819176
Breast Cancer Res. 2011;13(6):R113
pubmed: 22085699
Theranostics. 2021 Mar 11;11(11):5296-5312
pubmed: 33859748
Carcinogenesis. 2022 Jun 27;43(6):517-527
pubmed: 35616105
Int J Mol Sci. 2021 Jan 28;22(3):
pubmed: 33525332
Asian Pac J Cancer Prev. 2016;17(6):2953-7
pubmed: 27356717
Clin Cancer Res. 2017 Aug 15;23(16):4651-4661
pubmed: 28490464
Breast Cancer Res Treat. 2021 Dec;190(3):403-413
pubmed: 34596798
Oncotarget. 2016 Mar 22;7(12):13842-53
pubmed: 26871599
PLoS Med. 2008 Feb;5(2):e45
pubmed: 18303940
Clin Cancer Res. 2008 Apr 15;14(8):2502-10
pubmed: 18413843
J Bone Miner Res. 2017 Jul;32(7):1442-1454
pubmed: 28300321
Oncol Rep. 2016 Jun;35(6):3135-42
pubmed: 27035124
Nat Rev Cancer. 2021 Dec;21(12):767-785
pubmed: 34508247
Cancer Res. 2010 Sep 15;70(18):7042-52
pubmed: 20823155
Adv Exp Med Biol. 2010;709:95-107
pubmed: 21618891
Br J Cancer. 2019 Jan;120(1):128-138
pubmed: 29988113